Boehringer to give Germany first blood of its BP franchise defence
This article was originally published in Scrip
Boehringer Ingelheim is launching its combination antihypertensive, Twynsta (telmisartan plus amlodipine), in Germany on 21 October, making it the first EU launch market, after the company got the OK from the European Commission on 12 October. This comes after the EU CHMP gave the product the greenlight in July (scripintelligence.com 23 July 2010). The product was approved in the US in October 2009 and in Japan in July 2010.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.